$PAVM

PAVmed Inc. (Nasdaq: PAVM) will host a business update conference call on November 13, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss operations, growth strategy, and Q3 2026 financial results. The webcast will be available on the company's website, with a replay accessible for 30 days. PAVmed operates in medical devices, diagnostics, and digital health, with subsidiaries Lucid Diagnostics (Nasdaq: LUCD) and Veris Health.

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective as of October 21, 2026, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accre

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 9, 2026, PAVmed Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with A.G.P./Alliance Global Partners, as sales agent (the “ Agent ”), pursuant to which the Company may offer and sell, fr

PAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.

PAVmed reported Q2 2026 earnings call updates. Management said Veris is moving from pilot to full commercialization at Ohio State, with two-thirds of planned departments onboarded and a goal of 1,000 patient enrollments in year one. It plans early-2027 FDA 510(k) for Veris and a Q4 pre-submission for PortIO, citing first-in-human data.

PAVmed (PAVM) held its Q2 2026 earnings call. GAAP net loss was $5.5 million ($0.87/share) and non-GAAP adjusted loss was $1.7 million ($0.27/share). Revenue was $33,000, with pro forma income over $3 million. Cash was $3.8 million at June 30. Management discussed Veris, Lucid Diagnostics, and device regulatory timelines, including a targeted early-2027 510(k) submission for Veris.

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Luci

PAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001624326 0001624326 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report

PAVmed Inc. (PAVM) is projected to report a loss of 70 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article is very brief and provides no additional details.